STK405759 as a combination therapy with bortezomib or dexamethasone, in and multiple myeloma models

about

STK405759 as a combination therapy with bortezomib or dexamethasone, in and multiple myeloma models

Item

http://www.wikidata.org/entity/Q57174026

description

im Juli 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2018

@uk

name

STK405759 as a combination the ...... in and multiple myeloma models

@en

STK405759 as a combination the ...... in and multiple myeloma models

@nl

type

Item

label

STK405759 as a combination the ...... in and multiple myeloma models

@en

STK405759 as a combination the ...... in and multiple myeloma models

@nl

prefLabel

STK405759 as a combination the ...... in and multiple myeloma models

@en

STK405759 as a combination the ...... in and multiple myeloma models

@nl

P1476

STK405759 as a combination the ...... in and multiple myeloma models

@en

P2093

Abraham Avigdor

http://www.w3.org/2001/XMLSchema#string

Adrian Duek

http://www.w3.org/2001/XMLSchema#string

Arnon Nagler

http://www.w3.org/2001/XMLSchema#string

Gabriela Rozic

http://www.w3.org/2001/XMLSchema#string

Igor Koman

http://www.w3.org/2001/XMLSchema#string

Irit Shapira

http://www.w3.org/2001/XMLSchema#string

Lena Paukov

http://www.w3.org/2001/XMLSchema#string

Merav Leiba

http://www.w3.org/2001/XMLSchema#string

Ohad Bejamini

http://www.w3.org/2001/XMLSchema#string

Ziv Cohen

http://www.w3.org/2001/XMLSchema#string

P2860

Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab

Cancer statistics, 2016

Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol.

A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

VAD chemotherapy as remission induction for multiple myeloma.

Posaconazole-vincristine coadministration triggers seizure in a young female adult: a case report.

Tubulin-targeting agent combination therapies: dosing schedule could matter.

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.

P304

31367-31379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25825

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30140376

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

6101139

http://www.w3.org/2001/XMLSchema#string